Lebrikizumab Improves Atopic Dermatitis and ​Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: ​ Results From the ADapt Trial. J of Skin 2025, 9 (1), s512. https://doi.org/10.25251/skin.9.supp.512.